Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
|
| Abstract |
Cytopenias are important but less studied adverse events following chimeric antigen receptor-engineered T cell (CAR-T) therapy. In our analysis of patients with large cell lymphoma who received axicabtagene ciloleucel (axi-cel), we sought to determine the rate and risk factors of clinically significant short term cytopenias defined as grade ≥3 neutropenia, anemia, or thrombocytopenia, or treatment with growth factors or blood product transfusions between days 20-30 after axi-cel. Fifty-three pts received axi-cel during the study period and severe cytopenias were observed in 32 (60%) pts. Significant cytopenias were more common in non-responders (stable or progressive disease) vs. responders (partial or complete response) (100% vs. 70%; p = .01). In the multivariable model, platelet transfusion within a month before leukapheresis, number of red blood cell and platelet transfusions between leukapheresis to lymphodepletion, pre-lymphodepletion absolute neurophil count, pre-lymphodepletion lactate dehydrogenase, and number of dexamethasone treatments after CAR-T were significantly associated with severe cytopenias after axi-cel.
|
|---|---|
| Authors | Lorena Panaite, Qian Vicky Wu, Jenna Voutsinas, Erin Mullane, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Stephen D Smith, Ajay K Gopal, Christina Poh, Lorenzo Iovino, Cameron J Turtle, David G Maloney, Brian G Till, Jordan Gauthier, Mazyar Shadman |
| Journal | Leukemia & lymphoma (Leuk Lymphoma) Vol. 63 Issue 12 Pg. 2918-2922 (12 2022) ISSN: 1029-2403 [Electronic] United States |
| PMID | 35811554 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!